Multiple mechanisms of anti-cancer effects exerted by astaxanthin

Marine Drugs

Volumn 13, Issue 7, 2015, Pages 4310-4330

  Zhang, Li ^a   Wang, Handong ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Astaxanthin; Cancer; Molecular targets

Indexed keywords

ASTAXANTHIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT3 PROTEIN; TRANSCRIPTION FACTOR NRF2; ANTINEOPLASTIC AGENT; XANTHOPHYLL;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AUTOPHAGY; BLADDER CARCINOGENESIS; BREAST CANCER; CANCER THERAPY; CELL COMMUNICATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLON CARCINOGENESIS; DRUG ABSORPTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; MOUTH CANCER; NONHUMAN; OXIDATIVE STRESS; PROTEIN TARGETING; REVIEW; TISSUE DISTRIBUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GAP JUNCTION; SIGNAL TRANSDUCTION;

ALGAE; ANIMALIA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; GAP JUNCTIONS; HUMANS; NF-KAPPA B; SIGNAL TRANSDUCTION; XANTHOPHYLLS;

EID: 84938227836     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md13074310     Document Type: Review

References (138)

1. Pashkow, F. J.; Watumull, D. G.; Campbell, C. L. Astaxanthin: A novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am. J. Cardiol. 2008, 101, 58D-68D.
2. Miki, W.; Yamaguchi, K.; Konosu, S. Comparison of carotenoids in the ovaries of marine fish and shellfish. Comp. Biochem. Physiol. B 1982, 71, 7-11.
3. Guerin, M.; Huntley, M. E.; Olaizola, M. Haematococcus astaxanthin: Applications for human health and nutrition. Trends Biotechnol. 2003, 21, 210-216.
4. Zhang, X. S.; Zhang, X.; Zhou, M. L.; Zhou, X. M.; Li, N.; Li, W.; Cong, Z. X.; Sun, Q.; Zhuang, Z.; Wang, C. X.; et al. Amelioration of oxidative stress and protection against early brain injury by astaxanthin after experimental subarachnoid hemorrhage. J. Neurosurg. 2014, 121, 42-54.
5. Ikeda, Y.; Tsuji, S.; Satoh, A.; Ishikura, M.; Shirasawa, T.; Shimizu, T. Protective effects of astaxanthin on 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells. J. Neurochem. 2008, 107, 1730-1740.
6. Liu, X.; Shibata, T.; Hisaka, S.; Osawa, T. Astaxanthin inhibits reactive oxygen species-mediated cellular toxicity in dopaminergic SH-SY5Y cells via mitochondria-targeted protective mechanism. Brain Res. 2009, 1254, 18-27.
7. Shen, H.; Kuo, C. C.; Chou, J.; Delvolve, A.; Jackson, S. N.; Post, J.; Woods, A. S.; Hoffer, B. J.; Wang, Y.; Harvey, B. K. Astaxanthin reduces ischemic brain injury in adult rats. FASEB J. 2009, 23, 1958-1968.
8. Wu, Q.; Zhang, X. S.; Wang, H. D.; Zhang, X.; Yu, Q.; Li, W.; Zhou, M. L.; Wang, X. L. Astaxanthin activates nuclear factor erythroid-related factor 2 and the antioxidant responsive element (Nrf2-ARE) pathway in the brain after subarachnoid hemorrhage in rats and attenuates early brain injury. Mar. Drugs 2014, 12, 6125-6141.
9. Zhang, X. S.; Zhang, X.; Wu, Q.; Li, W.; Zhang, Q. R.; Wang, C. X.; Zhou, X. M.; Li, H.; Shi, J. X.; Zhou, M. L. Astaxanthin alleviates early brain injury following subarachnoid hemorrhage in rats: Possible involvement of Akt/bad signaling. Mar. Drugs 2014, 12, 4291-4310.
10. Lu, Y. P.; Liu, S. Y.; Sun, H.; Wu, X. M.; Li, J. J.; Zhu, L. Neuroprotective effect of astaxanthin on H (2) O (2)-induced neurotoxicity in vitro and on focal cerebral ischemia in vivo. Brain Res. 2010, 1360, 40-48.
11. Gross, G. J.; Lockwood, S. F. Cardioprotection and myocardial salvage by a disodium disuccinate astaxanthin derivative (Cardax). Life Sci. 2004, 75, 215-224.
12. Lauver, D. A.; Lockwood, S. F.; Lucchesi, B. R. Disodium Disuccinate Astaxanthin (Cardax) attenuates complement activation and reduces myocardial injury following ischemia/reperfusion. J. Pharmacol. Exp. Ther. 2005, 314, 686-692.
13. Fassett, R. G.; Coombes, J. S. Astaxanthin, oxidative stress, inflammation and cardiovascular disease. Future Cardiol. 2009, 5, 333-342.
14. Kavitha, K.; Kowshik, J.; Kishore, T. K.; Baba, A. B.; Nagini, S. Astaxanthin inhibits NF-kappaB and Wnt/beta-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer. Biochim. Biophys. Acta 2013, 1830, 4433-4444.
15. Tanaka, T.; Morishita, Y.; Suzui, M.; Kojima, T.; Okumura, A.; Mori, H. Chemoprevention of mouse urinary bladder carcinogenesis by the naturally occurring carotenoid astaxanthin. Carcinogenesis 1994, 15, 15-19.
16. Nagendraprabhu, P.; Sudhandiran, G. Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFkB and COX-2. Investig. New Drugs 2011, 29, 207-224.
17. Yasui, Y.; Hosokawa, M.; Mikami, N.; Miyashita, K.; Tanaka, T. Dietary astaxanthin inhibits colitis and colitis-associated colon carcinogenesis in mice via modulation of the inflammatory cytokines. Chem. Biol. Interact. 2011, 193, 79-87.
18. Zhang, X.; Zhao, W. E.; Hu, L.; Zhao, L.; Huang, J. Carotenoids inhibit proliferation and regulate expression of peroxisome proliferators-activated receptor gamma (PPARgamma) in K562 cancer cells. Arch. Biochem. Biophys. 2011, 512, 96-106.
19. Song, X. D.; Zhang, J. J.; Wang, M. R.; Liu, W. B.; Gu, X. B.; Lv, C. J. Astaxanthin induces mitochondria-mediated apoptosis in rat hepatocellular carcinoma CBRH-7919 cells. Biol. Pharm. Bull. 2011, 34, 839-844.
20. Song, X.; Wang, M.; Zhang, L.; Zhang, J.; Wang, X.; Liu, W.; Gu, X.; Lv, C. Changes in cell ultrastructure and inhibition of JAK1/STAT3 signaling pathway in CBRH-7919 cells with astaxanthin. Toxicol. Mech. Methods 2012, 22, 679-686.
21. Pinton, P.; Rizzuto, R. p66Shc, oxidative stress and aging: Importing a lifespan determinant into mitochondria. Cell Cycle 2008, 7, 304-308.
22. Ostan, R.; Lanzarini, C.; Pini, E.; Scurti, M.; Vianello, D.; Bertarelli, C.; Fabbri, C.; Izzi, M.; Palmas, G.; Biondi, F.; et al. Inflammaging and Cancer: A Challenge for the Mediterranean Diet. Nutrients 2015, 7, 2589-2621.
23. Liu, Y.; Yang, H.; Chen, T.; Luo, Y.; Xu, Z.; Li, Y.; Yang, J. Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma. PLoS ONE 2015, 10, e0127092.
24. Park, G. B.; Hur, D. Y.; Kim, D. Combining CAL-101 with Celecoxib Enhances Apoptosis of EBV-transformed B-Cells Through MAPK-induced ER Stress. Anticancer Res. 2015, 35, 2699-2708.
25. Xu, C.; Sun, X.; Qin, S.; Zheng, Z.; Xu, S.; Luo, G.; Liu, P.; Du, N.; Zhang, Y.; Liu, D.; et al. Let-7a regulates mammosphere formation capacity through Ras/NF-kappaB and Ras/MAPK/ERK pathway in breast cancer stem cells. Cell Cycle 2015, 14, 1686-1697.
26. Lauffenburger, D. A.; Horwitz, A. F. Cell migration: A physically integrated molecular process. Cell 1996, 84, 359-369.
27. Kowshik, J.; Baba, A. B.; Giri, H.; Deepak Reddy, G.; Dixit, M.; Nagini, S. Astaxanthin inhibits JAK/STAT-3 signaling to abrogate cell proliferation, invasion and angiogenesis in a hamster model of oral cancer. PLoS ONE 2014, 9, e109114.
28. Palozza, P.; Torelli, C.; Boninsegna, A.; Simone, R.; Catalano, A.; Mele, M. C.; Picci, N. Growth-inhibitory effects of the astaxanthin-rich alga Haematococcus pluvialis in human colon cancer cells. Cancer Lett. 2009, 283, 108-117.
29. Lo, A. C.; Woo, T. T.; Wong, R. L.; Wong, D. Apoptosis and other cell death mechanisms after retinal detachment: Implications for photoreceptor rescue. Ophthalmologica 2011, 226(Suppl. 1), 10-17.
30. Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007, 35, 495-516.
31. Zhang, X.; Chen, Y.; Jenkins, L. W.; Kochanek, P. M.; Clark, R. S. Bench-to-bedside review: Apoptosis/programmed cell death triggered by traumatic brain injury. Crit. Care 2005, 9, 66-75.
32. Ouyang, L.; Shi, Z.; Zhao, S.; Wang, F. T.; Zhou, T. T.; Liu, B.; Bao, J. K. Programmed cell death pathways in cancer: A review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012, 45, 487-498.
33. Hu, S.; Vincenz, C.; Buller, M.; Dixit, V. M. A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis. J. Biol. Chem. 1997, 272, 9621-9624.
34. Cohen, G. M. Caspases: The executioners of apoptosis. Biochem. J. 1997, 326(Pt 1), 1-16.
35. Glasauer, A.; Chandel, N. S. Targeting antioxidants for cancer therapy. Biochem. Pharmacol. 2014, 92, 90-101.
36. Cairns, R. A.; Harris, I. S.; Mak, T. W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11, 85-95.
37. Franceschelli, S.; Pesce, M.; Ferrone, A.; de Lutiis, M. A.; Patruno, A.; Grilli, A.; Felaco, M.; Speranza, L. Astaxanthin treatment confers protection against oxidative stress in U937 cells stimulated with lipopolysaccharide reducing O2-production. PLoS ONE 2014, 9, e88359.
38. Kim, K. N.; Heo, S. J.; Kang, S. M.; Ahn, G.; Jeon, Y. J. Fucoxanthin induces apoptosis in human leukemia HL-60 cells through a ROS-mediated Bcl-xL pathway. Toxicol. in Vitro 2010, 24, 1648-1654.
39. Balkwill, F.; Mantovani, A. Inflammation and cancer: Back to Virchow? Lancet 2001, 357, 539-545.
40. Franceschi, C.; Bonafe, M.; Valensin, S.; Olivieri, F.; de Luca, M.; Ottaviani, E.; de Benedictis, G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci. 2000, 908, 244-254.
41. Franceschi, C. Inflammaging as a major characteristic of old people: Can it be prevented or cured? Nutr. Rev. 2007, 65(12 Pt 2), S173-S176.
42. Franceschi, C.; Capri, M.; Monti, D.; Giunta, S.; Olivieri, F.; Sevini, F.; Panourgia, M. P.; Invidia, L.; Celani, L.; Scurti, M.; et al. Inflammaging and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in humans. Mech. Ageing Dev. 2007, 128, 92-105.
43. Cevenini, E.; Monti, D.; Franceschi, C. Inflamm-ageing. Curr. Opin. Clin. Nutr. Metab. Care 2013, 16, 14-20.
44. Coussens, L. M.; Werb, Z. Inflammation and cancer. Nature 2002, 420, 860-867.
45. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature 2008, 454, 436-444.
46. Karin, M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441, 431-436.
47. Chia, W. K.; Ali, R.; Toh, H. C. Aspirin as adjuvant therapy for colorectal cancer-Reinterpreting paradigms. Nat. Rev. Clin. Oncol. 2012, 9, 561-570.
48. Giraldo, N. A.; Becht, E.; Remark, R.; Damotte, D.; Sautes-Fridman, C.; Fridman, W. H. The immune contexture of primary and metastatic human tumours. Curr. Opin. Immunol. 2014, 27, 8-15.
49. Speranza, L.; Pesce, M.; Patruno, A.; Franceschelli, S.; de Lutiis, M. A.; Grilli, A.; Felaco, M. Astaxanthin treatment reduced oxidative induced pro-inflammatory cytokines secretion in U937: SHP-1 as a novel biological target. Mar. Drugs 2012, 10, 890-899.
50. Friedl, P.; Wolf, K. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat. Rev. Cancer 2003, 3, 362-374.
51. Nguyen, D. X.; Massague, J. Genetic determinants of cancer metastasis. Nat. Rev. Genet. 2007, 8, 341-352.
52. Guo, W.; Giancotti, F. G. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 2004, 5, 816-826.
53. Lu, K. W.; Chen, J. C.; Lai, T. Y.; Yang, J. S.; Weng, S. W.; Ma, Y. S.; Lu, P. J.; Weng, J. R.; Chueh, F. S.; Wood, W. G.; et al. Gypenosides inhibits migration and invasion of human oral cancer SAS cells through the inhibition of matrix metalloproteinase-2-9 and urokinase-plasminogen by ERK1/2 and NF-kappa B signaling pathways. Hum. Exp. Toxicol. 2011, 30, 406-415.
54. Brew, K.; Dinakarpandian, D.; Nagase, H. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim. Biophys. Acta 2000, 1477, 267-283.
55. Kozuki, Y.; Miura, Y.; Yagasaki, K. Inhibitory effects of carotenoids on the invasion of rat ascites hepatoma cells in culture. Cancer Lett. 2000, 151, 111-115.
56. Castellano, P.; Eugenin, E. A. Regulation of gap junction channels by infectious agents and inflammation in the CNS. Front. Cell Neurosci. 2014, 8, 122.
57. Evans, W. H.; Martin, P. E. Gap junctions: Structure and function (Review). Mol. Membr. Biol. 2002, 19, 121-136.
58. Lampe, P. D.; Lau, A. F. The effects of connexin phosphorylation on gap junctional communication. Int. J. Biochem. Cell Biol. 2004, 36, 1171-1186.
59. Willecke, K.; Eiberger, J.; Degen, J.; Eckardt, D.; Romualdi, A.; Guldenagel, M.; Deutsch, U.; Sohl, G. Structural and functional diversity of connexin genes in the mouse and human genome. Biol. Chem. 2002, 383, 725-737.
60. Hix, L. M.; Lockwood, S. F.; Bertram, J. S. Upregulation of connexin 43 protein expression and increased gap junctional communication by water soluble disodium disuccinate astaxanthin derivatives. Cancer Lett. 2004, 211, 25-37.
61. Hix, L. M.; Frey, D. A.; McLaws, M. D.; Osterlie, M.; Lockwood, S. F.; Bertram, J. S. Inhibition of chemically-induced neoplastic transformation by a novel tetrasodium diphosphate astaxanthin derivative. Carcinogenesis 2005, 26, 1634-1641.
62. Daubrawa, F.; Sies, H.; Stahl, W. Astaxanthin diminishes gap junctional intercellular communication in primary human fibroblasts. J. Nutr. 2005, 135, 2507-2511.
63. Karin, M.; Greten, F. R. NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5, 749-759.
64. Courtois, G.; Gilmore, T. D. Mutations in the NF-kappaB signaling pathway: Implications for human disease. Oncogene 2006, 25, 6831-6843.
65. Kang, M. R.; Kim, M. S.; Kim, S. S.; Ahn, C. H.; Yoo, N. J.; Lee, S. H. NF-kappaB signalling proteins p50/p105, p52/p100, RelA, and IKKepsilon are over-expressed in oesophageal squamous cell carcinomas. Pathology 2009, 41, 622-625.
66. Karin, M.; Lin, A. NF-kappaB at the crossroads of life and death. Nat. Immunol. 2002, 3, 221-227.
67. Wilken, R.; Veena, M. S.; Wang, M. B.; Srivatsan, E. S. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol. Cancer 2011, 10, 12.
68. Liao, D. J.; Thakur, A.; Wu, J.; Biliran, H.; Sarkar, F. H. Perspectives on c-Myc, Cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy. Crit. Rev. Oncog. 2007, 13, 93-158.
69. Shakibaei, M.; Harikumar, K. B.; Aggarwal, B. B. Resveratrol addiction: To die or not to die. Mol. Nutr. Food Res. 2009, 53, 115-128.
70. Christiaens, I.; Zaragoza, D. B.; Guilbert, L.; Robertson, S. A.; Mitchell, B. F.; Olson, D. M. Inflammatory processes in preterm and term parturition. J. Reprod. Immunol. 2008, 79, 50-57.
71. Ono, M. Molecular links between tumor angiogenesis and inflammation: Inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci. 2008, 99, 1501-1506.
72. Gupta, S. C.; Prasad, S.; Reuter, S.; Kannappan, R.; Yadav, V. R.; Ravindran, J.; Hema, P. S.; Chaturvedi, M. M.; Nair, M.; Aggarwal, B. B. Modification of cysteine 179 of IkappaBalpha kinase by nimbolide leads to down-regulation of NF-kappaB-regulated cell survival and proliferative proteins and sensitization of tumor cells to chemotherapeutic agents. J. Biol. Chem. 2010, 285, 35406-35417.
73. Ishaq, M.; Khan, M. A.; Sharma, K.; Sharma, G.; Dutta, R. K.; Majumdar, S. Gambogic acid induced oxidative stress dependent caspase activation regulates both apoptosis and autophagy by targeting various key molecules (NF-kappaB, Beclin-1, p62 and NBR1) in human bladder cancer cells. Biochim. Biophys. Acta 2014, 1840, 3374-3384.
74. Rawlings, J. S.; Rosler, K. M.; Harrison, D. A. The JAK/STAT signaling pathway. J. Cell Sci. 2004, 117, 1281-1283.
75. Leonard, W. J.; O'Shea, J. J. Jaks and STATs: Biological implications. Annu. Rev. Immunol. 1998, 16, 293-322.
76. Schindler, C.; Darnell, J. E., Jr. Transcriptional responses to polypeptide ligands: The JAK-STAT pathway. Annu. Rev. Biochem. 1995, 64, 621-651.
77. O'Shea, J. J.; Holland, S. M.; Staudt, L. M. JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med. 2013, 368, 161-170.
78. Morales, J. K.; Falanga, Y. T.; Depcrynski, A.; Fernando, J.; Ryan, J. J. Mast cell homeostasis and the JAK-STAT pathway. Genes Immun. 2010, 11, 599-608.
79. Chuang, P. Y.; He, J. C. JAK/STAT signaling in renal diseases. Kidney Int. 2010, 78, 231-234.
80. Kinoshita, S.; Ogawa, W.; Okamoto, Y.; Takashima, M.; Inoue, H.; Matsuki, Y.; Watanabe, E.; Hiramatsu, R.; Kasuga, M. Role of hepatic STAT3 in the regulation of lipid metabolism. Kobe J. Med. Sci. 2008, 54, E200-E208.
81. Mair, M.; Blaas, L.; Osterreicher, C. H.; Casanova, E.; Eferl, R. JAK-STAT signaling in hepatic fibrosis. Front. Biosci. Landmark Ed. 2011, 16, 2794-2811.
82. Xu, D.; Yin, C.; Wang, S.; Xiao, Y. JAK-STAT in lipid metabolism of adipocytes. JAKSTAT 2013, 2, e27203.
83. Zhu, S.; Wang, Z.; Li, Z.; Peng, H.; Luo, Y.; Deng, M.; Li, R.; Dai, C.; Xu, Y.; Liu, S.; et al. Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3. Oncotarget 2015, 6, 10460-10472.
84. Curran, E.; Corrales, L.; Kline, J. Targeting the innate immune system as immunotherapy for acute myeloid leukemia. Front. Oncol. 2015, 5, 83.
85. Bosch-Barrera, J.; Menendez, J. A. Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy. Cancer Treat. Rev. 2015, 41, 540-546.
86. Knecht, H.; Berger, C.; Rothenberger, S.; Odermatt, B. F.; Brousset, P. The role of Epstein-Barr virus in neoplastic transformation. Oncology 2001, 60, 289-302.
87. Chen, C. C.; Boxer, R. B.; Stairs, D. B.; Portocarrero, C. P.; Horton, R. H.; Alvarez, J. V.; Birnbaum, M. J.; Chodosh, L. A. Akt is required for Stat5 activation and mammary differentiation. Breast Cancer Res. 2010, 12, R72.
88. Gallipoli, P.; Cook, A.; Rhodes, S.; Hopcroft, L.; Wheadon, H.; Whetton, A. D.; Jorgensen, H. G.; Bhatia, R.; Holyoake, T. L. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood 2014, 124, 1492-501.
89. Owonikoko, T. K.; Khuri, F. R. Targeting the PI3K/AKT/mTOR pathway: Biomarkers of success and tribulation. Am. Soc. Clin. Oncol. Educ. Book 2013, 33, e395.
90. Borders, E. B.; Bivona, C.; Medina, P. J. Mammalian target of rapamycin: Biological function and target for novel anticancer agents. Am. J. Health Syst. Pharm. 2010, 67, 2095-2106.
91. Yap, T. A.; Garrett, M. D.; Walton, M. I.; Raynaud, F.; de Bono, J. S.; Workman, P. Targeting the PI3K-AKT-mTOR pathway: Progress, pitfalls, and promises. Curr. Opin. Pharmacol. 2008, 8, 393-412.
92. Liao, W. T.; Li, T. T.; Wang, Z. G.; Wang, S. Y.; He, M. R.; Ye, Y. P.; Qi, L.; Cui, Y. M.; Wu, P.; Jiao, H. L.; et al. microRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2. Clin. Cancer Res. 2013, 19, 4662-4672.
93. Zheng, J.; Zou, X.; Yao, J. The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells. Chemotherapy 2012, 58, 273-281.
94. Yothaisong, S.; Dokduang, H.; Techasen, A.; Namwat, N.; Yongvanit, P.; Bhudhisawasdi, V.; Puapairoj, A.; Riggins, G. J.; Loilome, W. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Tumour Biol. 2013, 34, 3637-3648.
95. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science 2002, 298, 1912-1934.
96. Younce, C. W.; Kolattukudy, P. E. MCP-1 causes cardiomyoblast death via autophagy resulting from ER stress caused by oxidative stress generated by inducing a novel zinc-finger protein, MCPIP. Biochem. J. 2010, 426, 43-53.
97. Yan, J.; Feng, Z.; Liu, J.; Shen, W.; Wang, Y.; Wertz, K.; Weber, P.; Long, J.; Liu, J. Enhanced autophagy plays a cardinal role in mitochondrial dysfunction in type 2 diabetic Goto-Kakizaki (GK) rats: Ameliorating effects of (-)-epigallocatechin-3-gallate. J. Nutr. Biochem. 2012, 23, 716-724.
98. Fan, S.; Qi, M.; Yu, Y.; Li, L.; Yao, G.; Tashiro, S.; Onodera, S.; Ikejima, T. P53 activation plays a crucial role in silibinin induced ROS generation via PUMA and JNK. Free Radic. Res. 2012, 46, 310-319.
99. Zhang, X.; Li, X.; Li, X.; Zheng, L.; Lei, L. ANXA1 silencing increases the sensitivity of cancer cells to low-concentration arsenic trioxide treatment by inhibiting ERK MAPK activation. Tumori 2015, 101, doi:10.5301/tj.5000315.
100. Baek, S. H.; Kim, C.; Lee, J. H.; Nam, D.; Lee, J.; Lee, S. G.; Chung, W. S.; Jang, H. J.; Kim, S. H.; Ahn, K. S. Cinobufagin exerts anti-proliferative and pro-apoptotic effects through the modulation ROS-mediated MAPKs signaling pathway. Immunopharmacol. Immunotoxicol. 2015, 37, 265-273.
101. Quintanilla, R. A.; Utreras, E.; Cabezas-Opazo, F. A. Role of PPAR gamma in the Differentiation and Function of Neurons. PPAR Res. 2014, 2014, 768594.
102. Sikka, S.; Chen, L.; Sethi, G.; Kumar, A. P. Targeting PPARgamma Signaling Cascade for the Prevention and Treatment of Prostate Cancer. PPAR Res. 2012, 2012, 968040.
103. Sporn, M. B.; Suh, N.; Mangelsdorf, D. J. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol. Med. 2001, 7, 395-400.
104. Venkatachalam, G.; Kumar, A. P.; Sakharkar, K. R.; Thangavel, S.; Clement, M. V.; Sakharkar, M. K. PPARgamma disease gene network and identification of therapeutic targets for prostate cancer. J. Drug Target. 2011, 19, 781-796.
105. Pignatelli, M.; Sanchez-Rodriguez, J.; Santos, A.; Perez-Castillo, A. 15-deoxy-Delta-12, 14-prostaglandin J2 induces programmed cell death of breast cancer cells by a pleiotropic mechanism. Carcinogenesis 2005, 26, 81-92.
106. Schumann, T.; Adhikary, T.; Wortmann, A.; Finkernagel, F.; Lieber, S.; Schnitzer, E.; Legrand, N.; Schober, Y.; Nockher, W. A.; Toth, P. M.; et al. Deregulation of PPARbeta/delta target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment. Oncotarget 2015, 6, 13416-13433.
107. Zhang, N.; Chu, E. S.; Zhang, J.; Li, X.; Liang, Q.; Chen, J.; Chen, M.; Teoh, N.; Farrell, G.; Sung, J. J.; et al. Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-kappaB signaling pathway. Oncotarget 2014, 5, 8330-8340.
108. Dinkova-Kostova, A. T.; Abramov, A. Y. The emerging role of Nrf2 in mitochondrial function. Free Radic. Biol. Med. 2015, in press.
109. Sekhar, K. R.; Freeman, M. L. NRF2 promotes survival following exposure to ionizing radiation. Free Radic. Biol. Med. 2015, in press.
110. Dinkova-Kostova, A. T.; Liby, K. T.; Stephenson, K. K.; Holtzclaw, W. D.; Gao, X.; Suh, N.; Williams, C.; Risingsong, R.; Honda, T.; Gribble, G. W.; et al. Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stress. Proc. Natl. Acad. Sci. USA 2005, 102, 4584-4589.
111. Kwak, M. K.; Itoh, K.; Yamamoto, M.; Sutter, T. R.; Kensler, T. W. Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione. Mol. Med. 2001, 7, 135-145.
112. Yan, W.; Wang, H. D.; Feng, X. M.; Ding, Y. S.; Jin, W.; Tang, K. The expression of NF-E2-related factor 2 in the rat brain after traumatic brain injury. J. Trauma. 2009, 66, 1431-1435.
113. Wang, J.; Fields, J.; Zhao, C.; Langer, J.; Thimmulappa, R. K.; Kensler, T. W.; Yamamoto, M.; Biswal, S.; Dore, S. Role of Nrf2 in protection against intracerebral hemorrhage injury in mice. Free Radic. Biol. Med. 2007, 43, 408-414.
114. Osburn, W. O.; Kensler, T. W. Nrf2 signaling: An adaptive response pathway for protection against environmental toxic insults. Mutat. Res. 2008, 659, 31-39.
115. Hayes, J. D.; McMahon, M. NRF2 and KEAP1 mutations: Permanent activation of an adaptive response in cancer. Trends Biochem. Sci. 2009, 34, 176-188.
116. Hayes, J. D.; McMahon, M. The double-edged sword of Nrf2: Subversion of redox homeostasis during the evolution of cancer. Mol. Cell 2006, 21, 732-734.
117. Kensler, T. W.; Wakabayashi, N. Nrf2: Friend or foe for chemoprevention? Carcinogenesis 2010, 31, 90-99.
118. Homma, S.; Ishii, Y.; Morishima, Y.; Yamadori, T.; Matsuno, Y.; Haraguchi, N.; Kikuchi, N.; Satoh, H.; Sakamoto, T.; Hizawa, N.; et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin. Cancer Res. 2009, 15, 3423-3432.
119. Yamadori, T.; Ishii, Y.; Homma, S.; Morishima, Y.; Kurishima, K.; Itoh, K.; Yamamoto, M.; Minami, Y.; Noguchi, M.; Hizawa, N. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Oncogene 2012, 31, 4768-4777.
120. Barros, M. P.; Marin, D. P.; Bolin, A. P.; de Cassia Santos Macedo, R.; Campoio, T. R.; Fineto, C., Jr.; Guerra, B. A.; Polotow, T. G.; Vardaris, C.; Mattei, R.; et al. Combined astaxanthin and fish oil supplementation improves glutathione-based redox balance in rat plasma and neutrophils. Chem. Biol. Interact. 2012, 197, 58-67.
121. Tanaka, T.; Shnimizu, M.; Moriwaki, H. Cancer chemoprevention by carotenoids. Molecules 2012, 17, 3202-3242.
122. During, A.; Harrison, E. H. Intestinal absorption and metabolism of carotenoids: Insights from cell culture. Arch. Biochem. Biophys. 2004, 430, 77-88.
123. Kistler, A.; Liechti, H.; Pichard, L.; Wolz, E.; Oesterhelt, G.; Hayes, A.; Maurel, P. Metabolism and CYP-inducer properties of astaxanthin in man and primary human hepatocytes. Arch. Toxicol. 2002, 75, 665-675.
124. Coral-Hinostroza, G. N.; Ytrestoyl, T.; Ruyter, B.; Bjerkeng, B. Plasma appearance of unesterified astaxanthin geometrical E/Z and optical R/S isomers in men given single doses of a mixture of optical 3 and 3'R/S isomers of astaxanthin fatty acyl diesters. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2004, 139, 99-110.
125. Kidd, P. Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Altern Med. Rev. 2011, 16, 355-364.
126. Reksodiputro, A. H. Autophagy. Acta Med. Indones. 2007, 39, 151-152.
127. Patel, A. S.; Lin, L.; Geyer, A.; Haspel, J. A.; An, C. H.; Cao, J.; Rosas, I. O.; Morse, D. Autophagy in idiopathic pulmonary fibrosis. PLoS ONE 2012, 7, e41394.
128. Lin, N. Y.; Beyer, C.; Giessl, A.; Kireva, T.; Scholtysek, C.; Uderhardt, S.; Munoz, L. E.; Dees, C.; Distler, A.; Wirtz, S.; et al. Autophagy regulates TNFalpha-mediated joint destruction in experimental arthritis. Ann. Rheum. Dis. 2013, 72, 761-768.
129. Codogno, P.; Meijer, A. J. Autophagy and signaling: Their role in cell survival and cell death. Cell Death Differ. 2005, 12(Suppl. 2), 1509-1518.
130. Zhang, L.; Wang, H.; Zhu, J.; Xu, J.; Ding, K. Mollugin induces tumor cell apoptosis and autophagy via the PI3K/AKT/mTOR/p70S6K and ERK signaling pathways. Biochem. Biophys. Res. Commun. 2014, 450, 247-254.
131. Zhang, L.; Wang, H.; Xu, J.; Zhu, J.; Ding, K. Inhibition of cathepsin S induces autophagy and apoptosis in human glioblastoma cell lines through ROS-mediated PI3K/AKT/mTOR/p70S6K and JNK signaling pathways. Toxicol. Lett. 2014, 228, 248-259.
132. Shen, M.; Chen, K.; Lu, J.; Cheng, P.; Xu, L.; Dai, W.; Wang, F.; He, L.; Zhang, Y.; Chengfen, W.; et al. Protective effect of astaxanthin on liver fibrosis through modulation of TGF-beta1 expression and autophagy. Mediat. Inflamm. 2014, 2014, 954502.
133. Li, J.; Xia, Y.; Liu, T.; Wang, J.; Dai, W.; Wang, F.; Zheng, Y.; Chen, K.; Li, S.; Abudumijiti, H.; et al. Protective effects of astaxanthin on ConA-induced autoimmune hepatitis by the JNK/p-JNK pathway-mediated inhibition of autophagy and apoptosis. PLoS ONE 2015, 10, e0120440.
134. Hayes, A. J.; Li, L. Y.; Lippman, M. E. Science, medicine, and the future. Antivascular therapy: A new approach to cancer treatment. BMJ 1999, 318, 853-856.
135. Pandya, N. M.; Dhalla, N. S.; Santani, D. D. Angiogenesis-A new target for future therapy. Vasc. Pharmacol. 2006, 44, 265-274.
136. Li, Y.; Kuscu, C.; Banach, A.; Zhang, Q.; Pulkoski-Gross, A.; Kim, D.; Liu, J.; Roth, E.; Li, E.; Shroyer, K. R.; et al. microRNA-181a-5p Inhibits Cancer Cell Migration and Angiogenesis via Downregulation of Matrix Metalloproteinase-14. Cancer Res. 2015, 75, 2674-2685.
137. Casey, S. C.; Amedei, A.; Aquilano, K.; Azmi, A. S.; Benencia, F.; Bhakta, D.; Bilsland, A. E.; Boosani, C. S.; Chen, S.; Ciriolo, M. R.; et al. Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin. Cancer Biol. 2015, in press.
138. Vredenburgh, J. J.; Desjardins, A.; Herndon, J. E., 2nd; Dowell, J. M.; Reardon, D. A.; Quinn, J. A.; Rich, J. N.; Sathornsumetee, S.; Gururangan, S.; et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 2007, 13, 1253-1259.